Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells

Gene Therapy

Volumn 23, Issue 1, 2016, Pages 18-25

  Sayroo, R ^a   Nolasco, D ^a   Yin, Z ^a   Colon Cortes, Y ^a   Pandya, M ^a   Ling, C ^a,b   Aslanidi, G ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS SEROTYPE 6 VECTOR; ARGINYLGLYCYLASPARTIC ACID; INTEGRIN; LYSINE; PARVOVIRUS VECTOR; PROTEOHEPARAN SULFATE; SERINE; THREONINE; TYROSINE; UNCLASSIFIED DRUG; ARGINYL-GLYCYL-ASPARTIC ACID; CAPSID PROTEIN; OLIGOPEPTIDE; RECOMBINANT PROTEIN;

ADENO ASSOCIATED VIRUS 6; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GENE THERAPY; CONTROLLED STUDY; GENE MUTATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LIVER CELL; MALE; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SITE DIRECTED MUTAGENESIS; TRANSGENE; TROPISM; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS ENTRY; WILD TYPE; ANIMAL; DEPENDOPARVOVIRUS; DISEASE MODEL; DRUG SCREENING; GENE THERAPY; GENE VECTOR; GENETICS; HEK293 CELL LINE; METABOLISM; NEOPLASMS; PLASMID; TUMOR CELL LINE; VIRAL TROPISM;

ANIMALS; CAPSID PROTEINS; CELL LINE, TUMOR; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HEPATOCYTES; HUMANS; MALE; MICE; NEOPLASMS; OLIGOPEPTIDES; PLASMIDS; RECOMBINANT PROTEINS; TRANSDUCTION, GENETIC; VIRAL TROPISM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955180984     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2015.89     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
2. Michelfelder S, Lee MK, deLima-Hahn E, Wilmes T, Kaul F, Muller O et al. Vectors selected from adeno-associated viral display peptide libraries for leukemia celltargeted cytotoxic gene therapy. Exp Hematol 2007; 35: 1766-1776
3. Muller OJ, Kaul F, Weitzman MD, Pasqualini R, Arap W, Kleinschmidt JA et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 2003; 21: 1040-1046
4. Bartel MA, Weinstein JR, Schaffer DV. Directed evolution of novel adenoassociated viruses for therapeutic gene delivery. Gene Ther 2012; 19: 694-700
5. Marsic D, Govindasamy L, Currlin S, Markusic DM, Tseng YS, Herzog RW et al. Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variants. Mol Ther 2014; 22: 1900-1909
6. Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther 2012; 20: 699-708
7. Flotte TR, Trapnell BC, Humphries M, Carey B, Calcedo R, Rouhani F et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther 2012; 22: 1239-1247
8. High KA, Aubourg P. rAAV human trial experience. Methods Mol Biol 2011; 807: 429-457
9. Harbison CE, Chiorini JA, Parrish CR. The parvovirus capsid odyssey: from the cell surface to the nucleus. Trends Microbiol 2008; 16: 208-214
10. Muzyczka N, Warrington KH. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum Gene Ther 2005; 16: 408-416
11. Vandenberghe LH, Wilson JM, Gao G. Tailoring the AAV vector capsid for gene therapy. Gene Ther 2009; 16: 311-319
12. Warrington Jr KH, Gorbatyuk OS, Harrison JK, Opie SR, Zolotukhin S, Muzyczka N. Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol 2004; 78: 6595-6609
13. Judd J, Wei F, Nguyen PQ, Tartaglia LJ, Agbandje-McKenna M, Silberg JJ et al. Random Insertion of mCherry Into VP3 Domain of Adeno-associated Virus Yields Fluorescent Capsids With no Loss of Infectivity. Mol Ther Nucleic Acids 2012; 1: e54
14. Konkalmatt PR, Deng D, Thomas S, Wu MT, Logsdon CD, French BA et al. Plectin-1 Targeted AAV Vector for the Molecular Imaging of Pancreatic Cancer. Front Oncol 2013; 3: 84
15. Shi W, Bartlett JS. RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther 2003; 7: 515-525
16. Grifman M, Trepel M, Speece P, Gilbert LB, Arap W, Pasqualini R et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 2001; 3: 964-975
17. Aslanidi GV, Rivers AE, Ortiz L, Song L, Ling C, Govindasamy L et al. Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?. PLoS One 2013; 8: e59142
18. Wu P, Xiao W, Conlon T, Hughes J, Agbandje-McKenna M, Ferkol T et al. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 2000; 74: 8635-8647
19. Wu Z, Asokan A, Grieger JC, Govindasamy L, Agbandje-McKenna M, Samulski RJ. Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J Virol. 2006; 80: 11393-11397
20. Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 2008; 105: 7827-7832
21. Lochrie MA, Tatsuno GP, Christie B, McDonnell JW, Zhou S, Surosky R et al. Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J Virol 2006; 80: 821-834
22. Kay CN, Ryals RC, Aslanidi GV, Min SH, Ruan Q, Sun J et al. Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PLoS One 2013; 8: e62097
23. Pandya J, Ortiz L, Ling C, Rivers AE, Aslanidi G. Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy. Immunol Cell Biol 2013; 92: 116-123
24. Petrs-Silva H, Dinculescu A, Li Q, Min S-H, Chiodo V, Pang J-J et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 2009; 17: 463-471
25. Ling C, Lu Y, Cheng B, McGoogan KE, Gee SW, Ma W et al. High-efficiency transduction of liver cancer cells by recombinant adeno-associated virus serotype 3 vectors. J Vis Exp 2011; e-pub ahead of print 22 March 2011; doi: 10.3791/2538
26. Markusic DM, Herzog RW, Aslanidi GV, Hoffman BE, Li B, Li M et al. High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol Ther 2010; 18: 2048-2056
27. Song L, Kauss MA, Kopin E, Chandra M, Ul-Hasan T, Miller E et al. Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo. Cytotherapy 2013; 15: 986-998
28. Aslanidi GV, Rivers AE, Ortiz L, Govindasamy L, Ling C, Jayandharan GR et al. High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors. Vaccine 2012; 30: 3908-3917
29. Zhong L, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M et al. Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology 2008; 381: 194-202
30. Ling C, Wang Y, Zhang Y, Ejjigani A, Yin Z, Lu Y et al. Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum Gene Ther 2014; 25: 1023-1034
31. Buijs PR, Verhagen JH, van Eijck CH, van Den Hoogen BG. Oncolytic viruses: From bench to bedside with a focus on safety. Hum Vaccin Immunother 2015; 11: 1573-1584
32. Burke J, Nieva J, Borad MJ, Breitbach CJ. Oncolytic viruses: perspectives on clinical development. Curr Opin Virol 2015; 13: 55-60
33. Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2014; 2: 295-300
34. Eager RM, Nemunaitis J. Clinical development directions in oncolytic viral therapy. Cancer Gene Ther 2011; 18: 305-317
35. Zarogoulidis P, Darwiche K, Sakkas A, Yarmus L, Huang H, Li Q et al. Suicide Gene Therapy for Cancer - Current Strategies. J Genet Syndr Gene Ther 2013; 4: 1-7
36. Duarte S, Carle G, Faneca H, de Lima MC, Pierrefite-Carle V. Suicide gene therapy in cancer: where do we stand now?. Cancer Lett 2012; 324: 160-170
37. Zhang YH, Wang Y, Yusufali AH, Ashby F, Zhang D, Yin ZF et al. Cytotoxic genes from traditional Chinese medicine inhibit tumor growth both in vitro and in vivo. J Integr Med 2014; 12: 483-494
38. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med 2013; 15: 65-77
39. Alam S, Bowser BS, Conway MJ, Israr M, Tandon A, Meyers C. Adeno-associated virus type 2 infection activates caspase dependent and independent apoptosis in multiple breast cancer lines but not in normal mammary epithelial cells. Mol Cancer 2011; 10: 97
40. Lisowski L, Dane AP, Chu K, Zhang Y, Cunningham SC, Wilson EM et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 2014; 506: 382-386
41. Seguin L, Desgrosellier JS, Weis SM, Cheresh DA. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol 2015; 25: 234-240
42. Koivunen E, Gay DA, Ruoslahti E. Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J Biol Chem 1993; 268: 20205-20210
43. Zhong L, Zhao W, Wu J, Li B, Zolotukhin S, Govindasamy L et al. A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol Ther 2007; 15: 1323-1330
44. Ng R, Govindasamy L, Gurda BL, McKenna R, Kozyreva OG, Samulski RJ et al. Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J Virol 2010; 84: 12945-12957
45. Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of receptorbinding in adeno-associated virus serotype 6 (AAV-6). Virology 2011; 420: 10-19
46. Ussher JE, Taylor JA. Optimized transduction of human monocyte-derived dendritic cells by recombinant adeno-associated virus serotype 6. Hum Gene Ther 2010; 21: 1675-1686
47. Qiao C, Zhang W, Yuan Z, Shin JH, Li J, Jayandharan GR et al. Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle. Hum Gene Ther 2010; 21: 1343-1348
48. Glushakova LG, Lisankie MJ, Eruslanov EB, Ojano-Dirain C, Zolotukhin I, Liu C et al. AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol Genet Metab 2009; 98: 289-299
49. Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites TJ et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002; 28: 158-167
50. Wang LN, Wang Y, Lu Y, Yin ZF, Zhang YH, Aslanidi GV et al. Pristimerin enhances recombinant adeno-associated virus vector-mediated transgene expression in human cell lines in vitro and murine hepatocytes in vivo. J Integr Med 2014; 12: 20-34